57 results
Page 2 of 3
8-K
EX-99.2
y791z
2 May 22
Rezolute, Inc. Announces Aggregate $130 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market
6:04am
8-K
EX-99.1
ygrp8k
23 Mar 22
Rezolute Announces Positive Results from the Phase 2b RIZE Study of RZ358 in Results to be presented in an oral presentation at a medical congress in 2Q 2022
4:03pm
424B5
2zytrv4bz1mn3g fc
14 Oct 21
Prospectus supplement for primary offering
4:07pm
424B5
u5zcmg7tjqm8qlohc
14 Oct 21
Prospectus supplement for primary offering
4:02pm
424B5
89kh 2gff
12 Oct 21
Prospectus supplement for primary offering
4:07pm
8-K
EX-99.1
b27ib70
23 Sep 21
Rezolute Presents Results from Two-Week Natural History Study in Congenital Hyperinsulinism Patients on Standard of Care Therapies at ESPE 2021
2:53pm
8-K
EX-99.1
hsvg3 zqak
13 Sep 21
Rezolute Announces Initiation of Dosing in the Second Cohort of its Phase 2b Trial of RZ358 for Tracking to Announce Top line data in Q1 2022
12:11pm
8-K
EX-10.1
nmcqk hx72pmlg8iib
4 Aug 21
Entry into a Material Definitive Agreement
12:00am
424B5
f4jf8eq9 mc64wt83d
4 Aug 21
Prospectus supplement for primary offering
12:00am
8-K
EX-10.1
42aqr2r
9 Oct 20
Rezolute Announces $41 Million Private Placement with Leading Investment Firms and Prepares to Imminently Up-list to Nasdaq
7:02pm
POS AM
bid8ai3qcv9ufgo8mrw
14 Oct 16
Prospectus update (post-effective amendment)
12:00am
POS AM
1ykfl2 cm
14 Oct 16
Prospectus update (post-effective amendment)
12:00am